|
Table S3.10 Antimicrobials included in analyses of Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme data
|
| səhifə | 9/26 | | tarix | 12.02.2017 | | ölçüsü | 388,53 Kb. | | #8296 |
|
Table S3.10 Antimicrobials included in analyses of Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme data
ATC code
|
Description
|
J01
|
Antibacterials for systemic use
|
A02BD
|
Combinations for eradication of Helicobacter pylori
|
A07AA09
|
Vancomycin (intestinal anti-infectives)
|
A07AA11
|
Rifaximin (intestinal anti-infectives)
|
D06AX09
|
Mupirocin (cream/ointment, RPBS only)
|
D06BA01
|
Sulfadiazine silver (cream)
|
D07CB01
|
Triamcinolone + neomycin sulfate + gramicidin + nystatin
|
S01AA01, S01AA11, S01AA12, S01AA26
|
Opthalmological antibiotics: gentamicin, chloramphenicol, azithromycin, tobramycin
|
S01AE01, S01AE03
|
Opthalmological fluoroquinolones: ofloxacin, ciprofloxacin
|
S02AA01, S02AA15
|
Otological anti-infectives: chloramphenicol, ciprofloxacin
|
S02CA
|
Corticosteroids and anti-infectives in combination
|
S03AA
|
Framycetin
|
RPBS = Repatriation Pharmaceutical Benefits Scheme
AURA 2016 Chapter 4: antimicrobial resistance tables Table S4.1 Acinetobacter baumannii resistance (all specimen sources), 2014
Antimicrobial
|
No. isolates tested
|
% resistant
|
Ampicillin
|
234
|
100.0
|
Ceftriaxone
|
776
|
83.9
|
Ciprofloxacin
|
562
|
4.1
|
Gentamicin
|
799
|
2.4
|
Trimethoprim–sulfamethoxazole
|
43
|
7.0
|
Meropenem
|
609
|
3.6
|
Sources: OrgTRx (Queensland); SNP (Queensland and northern New South Wales)
Table S4.2 Acinetobacter baumannii resistance, by clinical setting, 2014
Antimicrobial
|
Public hospitals and health services, % resistant (n)
|
Private hospitals, % resistant (n)
|
Community, % resistant (n)
|
Residential aged care facilities, % resistant (n)
|
Ampicillin
|
na
|
100.0 (54)
|
100.0 (165)
|
100.0 (15)
|
Ceftriaxone
|
80.1 (557)
|
100.0 (51)
|
92.2 (153)
|
86.7 (15)
|
Ciprofloxacin
|
4.2 (520)
|
2.4 (42)
|
na
|
na
|
Gentamicin
|
2.8 (567)
|
1.9 (54)
|
1.2 (163)
|
0.0 (15)
|
Trimethoprim–sulfamethoxazole
|
na
|
7.0 (43)
|
na
|
na
|
Meropenem
|
3.5 (564)
|
4.4 (45)
|
na
|
na
|
na = not available (either not tested or tested against an inadequate number of isolates)
Sources: OrgTRx; SNP (Queensland and northern New South Wales)
Table S4.3 Escherichia coli resistance, by specimen source, 2014
Antimicrobial
|
Blood, % resistant (n)
|
Urine, % resistant (n)
|
Other, % resistant (n)
|
Total, % resistant (n)
|
Ampicillin
|
51.3 (5 907)
|
42.3 (82 118)
|
49.8 (2 666)
|
43.1 (90 691)
|
Amoxicillin–clavulanate
|
20.9 (5 495)
|
11.1 (82 370)
|
21.1 (1 810)
|
11.9 (89 675)
|
Ticarcillin–clavulanate
|
18.9 (3 855)
|
33.7 (3 200)
|
na
|
25.6 (7 055)
|
Piperacillin–tazobactam
|
6.3 (5 902)
|
5.3 (25 457)
|
9.4 (2 167)
|
5.7 (33 526)
|
Cefazolin
|
19.4 (4 661)
|
15.2 (26 690)
|
25.0 (2 680)
|
16.6 (34 031)
|
Cefoxitin
|
na
|
5.5 (54 676)
|
na
|
5.5 (54 676)
|
Ceftriaxone
|
7.5 (5 903)
|
5.1 (29 176)
|
12.4 (2 243)
|
5.9 (37 322)
|
Ceftazidime
|
4.4 (3 485)
|
na
|
na
|
4.4 (3 485)
|
Cefepime
|
2.8 (3 888)
|
na
|
na
|
2.8 (3 888)
|
Trimethoprim
|
29.4 (3 485)
|
21.0 (82 109)
|
na
|
21.3 (85 594)
|
Trimethoprim–sulfamethoxazole
|
26.8 (5 902)
|
19.9 (26 369)
|
18.9 (2 677)
|
21.0 (34 948)
|
Gentamicin
|
7.0 (5 908)
|
4.5 (30 427)
|
6.0 (2 665)
|
5.0 (39 000)
|
Tobramycin
|
8.1 (3 886)
|
6.3 (3 212)
|
10.3 (436)
|
7.4 (7 534)
|
Amikacin
|
0.1 (3 485)
|
na
|
na
|
0.1 (3 485)
|
Ciprofloxacin
|
8.7 (5 898)
|
6.2 (25 684)
|
9.7 (2 144)
|
6.8 (33 726)
|
Norfloxacin
|
16.5 (3 485)
|
6.6 (79 916)
|
na
|
7.1 (83 401)
|
Nitrofurantoin
|
1.5 (3 462)
|
0.8 (54 605)
|
na
|
0.9 (58 067)
|
Meropenem
|
0.1 (5 886)
|
0.0 (25 548)
|
0.0 (2 183)
|
0.0 (33 617)
|
na = not available (either not tested or tested against an inadequate number of isolates)
Sources: OrgTRx (Queensland); AGAR (national); SNP (Queensland and northern New South Wales)
Dostları ilə paylaş: |
|
|
